Literature DB >> 12672036

Plasma sex steroid hormones and breast cancer risk in Chinese women.

Herbert Yu1, Xiao-Ou Shu, Runhua Shi, Qi Dai, Fan Jin, Yu-Tang Gao, Benjamin D L Li, Wei Zheng.   

Abstract

Estrogens regulate the growth and differentiation of mammary cells and play an important role in the development of breast cancer. High circulating levels of estrogens are associated with increased risk of breast cancer in Caucasian women. Because Asian women have low estrogens in the circulation compared with their Caucasian counterparts, the effect of estrogens on breast cancer risk in populations with low circulating estrogens remains to be elucidated. We conducted a population-based case-control study in China to evaluate the association of sex steroid hormones with breast cancer risk in Chinese women. Our study included 300 incident cases with primary breast cancer and 300 age- and menopausal status-matched healthy controls randomly selected from the general population in Shanghai. Fasting blood samples were collected from cases prior to any treatment and from their matched controls. Commercial immunoassays were used to measure plasma concentrations of estradiol, estrone, estrone sulfate, testosterone, progesterone, dehydroepiandrosteindian sulfate (DHEA-S) and steroid hormone-binding globulin (SHBG). Conditional logistic regression analysis was performed to examine the association between steroid hormones and breast cancer risk. The results showed that breast cancer risk was elevated with increasing levels of estrone and testosterone (p for trend < 0.05) but not with DHEA-S, estradiol, estrone sulfate, progesterone or SHBG. The estimated relative risks between upper and lower tertiles were 2.07 (95% confidence interval [CI] 0.97-4.41) for estrone in postmenopausal women, 2.01 (95% CI 0.96-4.21) for testosterone in premenopausal women, and 2.40 (95% CI 1.11-5.21) for testosterone in postmenopausal women, after adjusting for age at first live birth, waist-to-hip ratio, total calorie intake, a history of fibroadenoma, a family history of breast cancer and SHBG. These results, in general, are consistent with the findings in Caucasian women and indicate that high sex steroid hormones in the circulation, both androgen and estrogen, are associated with increased risk of breast cancer even in populations with relatively low sex hormones. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672036     DOI: 10.1002/ijc.11034

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.

Authors:  J Feng; L Li; N Zhang; J Liu; L Zhang; H Gao; G Wang; Y Li; Y Zhang; X Li; D Liu; J Lu; B Huang
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

Review 2.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

3.  Effects of aerobic exercise on premenopausal sex hormone levels: results of the WISER study, a randomized clinical trial in healthy, sedentary, eumenorrheic women.

Authors:  Alma J Smith; William R Phipps; Andrea Y Arikawa; Maureen O'Dougherty; Beth Kaufman; William Thomas; Kathryn H Schmitz; Mindy S Kurzer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-05       Impact factor: 4.254

4.  Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study.

Authors:  Christy G Woolcott; Yurii B Shvetsov; Frank Z Stanczyk; Lynne R Wilkens; Kami K White; Christian Caberto; Brian E Henderson; Loïc Le Marchand; Laurence N Kolonel; Marc T Goodman
Journal:  Endocr Relat Cancer       Date:  2010-02-18       Impact factor: 5.678

Review 5.  Amelioration of sexual adverse effects in the early breast cancer patient.

Authors:  Michelle E Melisko; Mindy Goldman; Hope S Rugo
Journal:  J Cancer Surviv       Date:  2010-07-04       Impact factor: 4.442

6.  Fat/fiber intakes and sex hormones in healthy premenopausal women in USA.

Authors:  Mylène Aubertin-Leheudre; Sherwood Gorbach; Margo Woods; Johanna T Dwyer; Barry Goldin; Herman Adlercreutz
Journal:  J Steroid Biochem Mol Biol       Date:  2008-08-09       Impact factor: 4.292

7.  Mammary gland and endometrial effects of testosterone in combination with oral estradiol and progesterone.

Authors:  Charles E Wood; Cynthia J Lees; J Mark Cline
Journal:  Menopause       Date:  2009 May-Jun       Impact factor: 2.953

8.  Timing clinic visits to phases of the menstrual cycle by using a fertility monitor: the BioCycle Study.

Authors:  Penelope P Howards; Enrique F Schisterman; Jean Wactawski-Wende; Jennifer E Reschke; Andrea A Frazer; Kathleen M Hovey
Journal:  Am J Epidemiol       Date:  2008-10-30       Impact factor: 4.897

9.  Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease.

Authors:  Glenn D Braunstein; B Delia Johnson; Frank Z Stanczyk; Vera Bittner; Sarah L Berga; Leslee Shaw; T Keta Hodgson; Maura Paul-Labrador; Ricardo Azziz; C Noel Bairey Merz
Journal:  J Clin Endocrinol Metab       Date:  2008-08-26       Impact factor: 5.958

10.  Pre-treatment high body mass index is associated with poor survival in Asian premenopausal women with localized breast cancer.

Authors:  Yung-Chang Lin; Hsiao-Hsiang Cheng; Shin-Cheh Chen; Wen-Chi Shen; Yi-Ting Huang
Journal:  J Cancer       Date:  2021-05-27       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.